TABLE 1.
Role of ferroptosis in drug resistance and the strategy to overcome treatment resistance in cancer.
| Treatment strategy | Treatment | Cancer type | Strategy to overcome resistance | References |
|---|---|---|---|---|
| Chemotherapy | Cisplatin | Head and neck cancer | CDDP + erastin and sulfasalazine | Roh et al. (2016) |
| Head and neck cancer | CDDP + Artesunate | Roh et al. (2017) | ||
| Osteosarcoma | CDDP + Erastin and RSL3 | Liu and Wang (2019) | ||
| Ovarian cancer | CDDP + Erastin | Li et al. (2020) | ||
| Gastric cancer | CDDP + Erastin | Haiyang Zhang et al. (2020) | ||
| Non-small-cell lung cancer | CDDP + RSL3 | Deng et al. (2021) | ||
| Gastric cancer | CDDP + erastin RSL3 or antagonist liproxstatin-1 | Dazhi Fu et al. (2021) | ||
| Subcutaneous tumor | CDDP+11β-hydroxy-ent-16-kaurene-15-one | Yong Sun et al. (2021) | ||
| Pancreatic adenocarcinoma | CDDP + gemcitabine | Wei et al. (2022) | ||
| Ovarian cancer | CDDP + mTOR inhibitor | Hua-Wen Li et al. (2022) | ||
| Triple-negative breast cancer | CDDP + HLF-knockdown | Hengyu Li et al. (2022) | ||
| Oxaliplatin | Colorectal cancer | Oxaliplatin + RSL3 | Changshun Yang et al. (2021) | |
| Colorectal cancer | Oxaliplatin + GPX4 inhibitor | Changshun Yang et al. (2021) | ||
| Platinum | Non-small-cell lung cancer | Platinum + GPX4 inhibitor | Wenwen Liu et al. (2021) | |
| Chemotherapy | Docetaxel | Ovarian cancer | Erastin + Docetaxel | Zhou et al. (2019) |
| Paclitaxel | Uterine serous carcinoma | Paclitaxel + Sulfasalazine | Sugiyama et al. (2020) | |
| Gemcitabine | Pancreatic cancer | ARF6 abrogation | Zeng Ye et al. (2020) | |
| Pancreatic cancer | Gemcitabine + RSL3 | Tang et al. (2020) | ||
| 5-fluorouracil | Colorectal cancer | Gemcitabine + Ferroptosis inducer | Chaudhary et al. (2021) | |
| Temozolomide | Glioblastoma | Temozolomide + ALZ003 upregulation | Xin Chen et al. (2020) | |
| Targeted therapy | Sunitinib | Renal cell carcinoma | Sunitinib + Artesunate | Markowitsch et al. (2020) |
| Sorafenib | Hepatocellular carcinoma | Sorafenib + Metallothionein (MT)-1G inhibition | Sun et al. (2016) | |
| Gastric cancer | Sorafenib + Sirtuins 6 inhibition | Cai et al. (2021) | ||
| Hepatocellular carcinoma | Sorafenib + ABCC5 inhibition | Huang et al. (2021) | ||
| Hepatocellular carcinoma | Sorafenib + Targeting YAP/TAZ or ATF4 | Gao et al. (2021) | ||
| Targeted therapy | Gefitinib | Non-small-cell lung cancer | Gefitinib + GPX4 inhibition | Viswanathan et al. (2017) |
| Cetuximab (anti-EGFR antibody) | Colorectal cancer | Cetuximab + Vitamin C | Lorenzato et al. (2020) | |
| EGFR-TKIs | EGFR-activating mutant lung adenocarcinoma | EGFR-TKIs + Vorinostat | Zhang et al. (2021) | |
| Androgen Receptor inhibitors | Prostate cancer | Androgen Receptor inhibitors +2,4-dienoyl-CoA reductase (DECR1) | Blomme et al. (2020) | |
| Prostate cancer | Androgen Receptor inhibitors + GPX4 inhibition | Tousignant et al. (2020) | ||
| Prostate cancer | Androgen Receptor inhibitors +2,4-dienoyl-CoA reductase (DECR1) | Nassar et al. (2020) | ||
| BRAF inhibitor | Melanoma | BRAF inhibition + Target SREBF2 | Hong et al. (2021) | |
| Vemurafenib | Melanoma | Vemurafenib + Ferroptosis-inducing drugs | Tsoi et al. (2018) | |
| Abemaciclib, Sorafenib | Hepatocellular carcinoma | Sorafenib + PSTK inhibition | Chen et al. (2022) | |
| Lapatinib | Non-small-cell lung cancer | Lapatinib + GPX4 inhibition | Ni et al. (2021) | |
| Multi-drug | Multi-drug resistance | Drug-resistant Breast Cancer Cells | Basic therapy + Pt-AuNS prodrugs | Del Valle et al. (2020) |
| Multi-drug | Multi-drug resistance | Various sensitive and drug-resistant phenotypes | Standard treatment + Ardisiacrispin B | Mbaveng et al. (2018b) |
| Various sensitive and drug-resistant cell lines | Basic therapy + Epunctanone | Mbaveng et al. (2018a) | ||
| Various sensitive and drug-resistant cell lines (leukemia cells) | Basic therapy + Ungeremine | Mbaveng et al. (2019) | ||
| Multiple drugs | Lapatinib, Erlotinib | Breast cancer, Non-small-cell lung cancer, ovarian cancer, melanoma | Standard treatment + GPX4 inhibition | Hangauer et al. (2017) |
| Carboplatin, Paclitaxel, Vemurafenib, Dabrafenib, Trametinib, Dabrafenib | ||||
| Immunotherapy | Anti-PD-1/PD-L1 blockade | Mammary carcinoma | Anti-PD-1/PD-L1 blockade + TYRO3 inhibition | Zhou Jiang et al. (2021) |
| Bladder cancer | Anti-PD-1/PD-L1 blockade + ACSL4activation | Liao et al. (2022) | ||
| Radiotherapy | Radiation | Clinically relevant radioresistant (CRR) cells | Basic therapy + miR-7-5p knockdown | Tomita et al. (2021) |
| Lung cancer, fibrosarcoma cell, breast adenocarcinoma cell | Ionizing radiation + Ferroptosis inducers | Lei et al. (2020) |